Druker Details a Career of Determination, Patient Impact, and Family Success

December 24, 2020
OncLive Staff

In our exclusive interview, Brian Druker, MD, discusses his journey into the field of oncology, the research that led to the initial approval of imatinib, why awards don’t impact his view on cancer care, and how becoming a family man has made him a better physician and scientist.

Welcome to a special edition of OncLive On Air. I'm your host today, Jason Harris.

OncLive On Air is a podcast from OncLive, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technologies, to treatment advances, to important regulatory decisions.

In today's episode, we spoke with Brian Druker, MD, of Oregon Health & Science University.

In our exclusive interview, Druker discussed his journey into the field of oncology, the research that led to the initial approval of imatinib (Gleevec), why awards don’t impact his view on cancer care, and how becoming a family man has made him a better physician and scientist.

Related Content:

Podcasts | Hematologic Oncology

x